较高的总omega-3PUFA水平和较低的omega-6:omega-3比率与阿尔茨海默病的下叶体积有关
M Emam1,2, Sara Albadri3, Amna Mohamed Ahmed4
1Department of Radiologic Technology, College of Applied Medical Sciences, Qassim University, Buraidah, 51452, Saudi Arabia.
Molecular neurobiology
|March 6, 2026
概括
较高的omega-3脂肪酸摄入量和较低的omega-6与omega-3比率与阿尔茨海默病患者的叶体积减少有关. 在认知正常或轻度认知障碍组中没有观察到这些发现.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 老年学是指老年学的学科.
背景情况:
- 脂肪酸对大脑健康起着作用,但它们对神经认知障碍的影响尚不清楚.
- 以前的研究表明,关于脂肪酸和认知功能/大脑结构的发现不一致.
- 需要先进的神经成像来澄清这些关系.
研究的目的:
- 为了研究血清脂肪酸水平与叶体积之间的关联.
- 为了在认知正常 (CN),轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 群体中比较这些关联.
- 探索脂肪酸与不同认知状态中的认知功能之间的关系.
主要方法:
- 分析血清脂肪酸水平的横截面研究 (omega-3 PUFAs,omega-6 PUFAs,omega-6:omega-3比率,MUFAs,SFAs).
- 使用神经成像技术评估叶体积.
- 根据年龄,性别,教育程度和APOE ε4等位基因状态进行调整.
主要成果:
- 在叶体积中发现了显著的差异,阿尔茨海默病患者的减少更大.
- 仅在AD组中,较高的omega-3PUFA水平和较低的omega-6:omega-3比率与叶体积减少有关.
- 在CN或MCI组中没有发现与叶体积的显著脂质关联.
- 在CN组中,较高的MUFA和SFAs与较差的认知分数相关.
结论:
- 较高的omega-3PUFA摄入量和较低的omega-6:omega-3比率与阿尔茨海默病患者的叶体积减少有关,而不是使用补充剂.
- 这些关联是针对阿尔茨海默氏症组的特异性,表明在疾病进展中可能发挥作用.
- 认知正常个体的研究结果表明,MUFA和SFA可能会影响认知功能.
- 由于研究设计,无法确定因果关系;需要进一步研究.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Role of Neurotransmitters in Memory
2.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


